Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans

BACKGROUND: Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol and apolipoprotein B100 (apoB). Although studies in mice and cells have identified increased hepatic LDL receptors as the basis for LDL lowe...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Circulation
Päätekijät: Reyes-Soffer, Gissette, Pavlyha, Marianna, Ngai, Colleen, Thomas, Tiffany, Holleran, Stephen, Ramakrishnan, Rajasekhar, Karmally, Wahida, Nandakumar, Renu, Fontanez, Nelson, Obunike, Joseph, Marcovina, Santica M., Lichtenstein, Alice H., Matthan, Nirupa R., Matta, James, Maroccia, Magali, Becue, Frederic, Poitiers, Franck, Swanson, Brian, Cowan, Lisa, Sasiela, William J., Surks, Howard K., Ginsberg, Henry N.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Lippincott Williams & Wilkins 2017
Aiheet:
Original Research Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5262523/
https://ncbi.nlm.nih.gov/pubmed/27986651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.116.025253
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia